DOCETAXEL ACCORD 20 mg/ml Vial 4 ml

Docetaxel Accord 20 mg/ml Vial is a powerful prescription-only medication used in the treatment of various types of cancer. Manufactured by Accord Healthcare, this cytotoxic agent belongs to the taxoid class of antineoplastic drugs, designed to inhibit the growth and spread of cancer cells. It is administered intravenously by qualified healthcare professionals in a clinical setting.

Product Details

• Principle: Docetaxel
• Strength: 20 mg/ml
• Form: Solution for infusion
• Package Size: 4 ml Vial
• Legal Status: Prescription Only Medicine (POM)
• Manufacturer: Accord Healthcare

Benefits of Use

Docetaxel Accord is indicated for the treatment of several advanced cancers, either alone or in combination with other therapeutic agents. Its primary benefits include:

• Effective in treating metastatic breast cancer.
• Used for non-small cell lung cancer, including locally advanced or metastatic forms.
• Plays a crucial role in the management of hormone-refractory prostate cancer.
• Applicable for advanced gastric adenocarcinoma.
• Utilized in head and neck squamous cell carcinoma.
• Works by disrupting the microtubule network essential for cell division, thereby inhibiting cancer cell proliferation.

How to Use

Docetaxel Accord must only be administered by healthcare professionals experienced in the use of cytotoxic chemotherapy agents. The following steps outline the general administration protocol:

1. Preparation: The solution must be diluted before infusion according to specific clinical guidelines and product instructions.
2. Dosage: The dose and administration schedule are individualized based on the patient's cancer type, body surface area, and overall medical condition, as determined by the treating physician.
3. Administration: Administered as a 1-hour intravenous infusion, usually every three weeks.
4. Premedication: Patients typically receive premedication with corticosteroids (e.g., dexamethasone) to reduce the incidence and severity of hypersensitivity reactions and fluid retention.
5. Monitoring: Patients require close monitoring during and after infusion for adverse reactions and treatment efficacy.

Caution & Warnings

• For Professional Use Only: This medication is for hospital or clinic administration by oncology specialists. Not for self-administration.
• Hypersensitivity Reactions: Severe allergic reactions can occur; premedication is crucial.
• Myelosuppression: Bone marrow suppression, leading to neutropenia, anemia, and thrombocytopenia, is common. Regular blood counts are essential.
• Fluid Retention: Significant fluid retention can occur, requiring careful management.
• Neurotoxicity: Peripheral neuropathy can develop, manifesting as paresthesia, dysesthesia, or pain.
• Liver Dysfunction: Monitor liver function tests, as docetaxel is extensively metabolized by the liver.
• Pregnancy and Lactation: Docetaxel is contraindicated during pregnancy and breastfeeding due to potential harm to the fetus or infant. Effective contraception is required for patients of reproductive potential.
• Drug Interactions: Caution with concomitant use of strong CYP3A4 inhibitors/inducers.

Ingredients

• Active Ingredient: Docetaxel
• Excipients: Polysorbate 80, Ethanol, and Water for injection (in the concentrate and diluent if applicable, depends on specific formulation).

Storage Conditions

Store unopened vials at room temperature (below 25°C), protected from light. Do not refrigerate or freeze. Once diluted, the solution stability will vary; refer to specific product instructions for storage of diluted solutions.